Literature DB >> 6531752

Assessment of anti-streptokinase antibody levels in human sera using a microradioimmunoassay procedure.

D M Moran, R Standring, E A Lavender, G S Harris.   

Abstract

A high capacity, quantitative radioimmunoassay procedure has been developed to measure IgG antibodies to streptokinase (SK) in human serum. Results showed that the use of low concentrations of 125I-SK (100 ng/ml) and ambient temperature incubation conditions minimised degradation of the target labelled antigen and afforded antibody binding values which could be confidently related to the native intact SK protein. SK-complexed to plasminogen was also shown to retain the equivalent antigenic activity of native SK. Comparison of the absolute anti-SK levels with streptokinase resistance titres demonstrated that the two measurements of antibody correlated statistically but afforded quantitatively poor agreements. A survey of IgG levels to SK in sera from 93 normal healthy volunteers showed that all individuals displayed readily measurable anti-SK antibodies, with some 80% having IgG concentration capable of binding in excess of 1 microgram SK per ml serum.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6531752

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system.

Authors:  D E Mosedale; D J Grainger
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.

Authors:  S C Grant
Journal:  Br Heart J       Date:  1992-05

3.  Thrombolytic treatment for recurrent myocardial infarction.

Authors:  H White
Journal:  BMJ       Date:  1991-02-23

4.  A rapid agglutination assay to detect anti-streptokinase antibodies.

Authors:  J P McRedmond; N T Mulvihill; M Kane; B Burke; B Aloul; T Forde; M Walsh; D J Fitzgerald
Journal:  Ir J Med Sci       Date:  2004 Oct-Dec       Impact factor: 1.568

Review 5.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.

Authors:  H D White; D B Cross; B F Williams; R M Norris
Journal:  Br Heart J       Date:  1990-09

7.  Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.

Authors:  R Fears; H Ferres; M Hibbs; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Evidence for the progressive uptake of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro.

Authors:  R Fears; H Ferres; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

9.  The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma.

Authors:  R Fears; H Ferres; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.

Authors:  R Fears; H Ferres; E Glasgow; R Standring; K J Hogg; J D Gemmill; J M Burns; A P Rae; F G Dunn; W S Hillis
Journal:  Br Heart J       Date:  1992-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.